CoChat

Detailed genetic and functional analysis of the hDMDdel52/ mdx mouse model

Yavas, Alper, Weij, Rudie, van Putten, Maaike, Kourkouta, Eleni, Beekman, Chantal, Puoliväli, Jukka, Bragge, Timo, Ahtoniemi, Toni, Knijnenburg, Jeroen, Hoogenboom, Marlies Elisabeth, Ariyurek, Yavuz, Aartsma-Rus, Annemieke, van Deutekom, Judith, Datson, Nicole · 2020 · PLOS ONE
Cited by 33

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Duchenne muscular dystrophy (DMD) is a severe, progressive neuromuscular disorder caused by reading frame disrupting mutations in the DMD gene leading to absence of functional dystrophin. Antisense oligonucleotide (AON)-mediated exon skipping is a therapeutic approach aimed at restoring the reading frame at the pre-mRNA level, allowing the production of internally truncated partly functional dystrophin proteins. AONs work in a sequence specific manner, which warrants generating humanized mouse models for preclinical tests. To address this, we previously generated the hDMDdel52/mdx mouse model using transcription activator like effector nuclease (TALEN) technology. This model contains mutated murine and human DMD genes, and therefore lacks mouse and human dystrophin resulting in a dystrophic phenotype. It allows preclinical evaluation of AONs inducing the skipping of human DMD exons 51 and 53 and resulting in restoration of dystrophin synthesis. Here, we have further characterized this model genetically and functionally. We discovered that the hDMD and hDMDdel52 transgene is present twice per locus, in a tail-to-tail-orientation. Long-read sequencing revealed a partial deletion of exon 52 (first 25 bp), and a 2.3 kb inversion in intron 51 in both copies. These new findings on the genomic make-up of the hDMD and hDMDdel52 transgene do not affect exon 51 and/or 53 skipping, but do underline the need for extensive genetic analysis of mice generated with genome editing techniques to elucidate additional genetic changes that might have occurred. The hDMDdel52/mdx mice were also evaluated functionally using kinematic gait analysis. This revealed a clear and highly significant difference in overall gait between hDMDdel52/mdx mice and C57BL6/J controls. The motor deficit detected in the model confirms its suitability for preclinical testing of exon skipping AONs for human DMD at both the functional and molecular level.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0244215

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 32

  1. SJ Moat, 2013, Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK), European journal of human genetics: EJHG, 21, 1049, 10.1038/ejhg.2012.301 · DOI · Paper page
  2. QQ Gao, 2015, The Dystrophin Complex: Structure, Function, and Implications for Therapy, Compr Physiol, 5, 1223
  3. EP Rader, 2016, Role of dystroglycan in limiting contraction-induced injury to the sarcomeric cytoskeleton of mature skeletal muscle, 113, 10992
  4. M Pane, 2013, Early neurodevelopmental assessment in Duchenne muscular dystrophy, Neuromuscular disorders: NMD, 23, 451, 10.1016/j.nmd.2013.02.012 · DOI
  5. Y Shimizu-Motohashi, 2016, Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trials, American journal of translational research, 8, 2471
  6. F Muntoni, 2011, Targeting RNA to treat neuromuscular disease, Nature reviews Drug discovery, 10, 621, 10.1038/nrd3459 · DOI
  7. F Muntoni, 2003, Dystrophin and mutations: one gene, several proteins, multiple phenotypes, The Lancet Neurology, 2, 731, 10.1016/S1474-4422(03)00585-4 · DOI · Paper page
  8. RG Hendriksen, 2015, A possible role of dystrophin in neuronal excitability: a review of the current literature, Neurosci Biobehav Rev, 51, 255, 10.1016/j.neubiorev.2015.01.023 · DOI
  9. A Aartsma-Rus, 2006, Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule, Muscle & nerve, 34, 135, 10.1002/mus.20586 · DOI · Paper page
  10. CL Bladen, 2015, The TREAT-NMD DMD Global Database: analysis of more than 7,000 Duchenne muscular dystrophy mutations, Human mutation, 36, 395, 10.1002/humu.22758 · DOI · Paper page
  11. R Maruyama, 2018, Creation of DMD Muscle Cell Model Using CRISPR-Cas9 Genome Editing to Test the Efficacy of Antisense-Mediated Exon Skipping, Methods Mol Biol, 1828, 165, 10.1007/978-1-4939-8651-4_10 · doi:10.1007/978-1-4939-8651-4_10
  12. U Akpulat, 2018, Shorter Phosphorodiamidate Morpholino Splice-Switching Oligonucleotides May Increase Exon-Skipping Efficacy in DMD, Mol Ther Nucleic Acids, 13, 534, 10.1016/j.omtn.2018.10.002 · DOI
  13. JG Andrews, 2018, Duchenne and Becker muscular dystrophy in adolescents: current perspectives, Adolesc Health Med Ther, 9, 53, 10.2147/AHMT.S125739 · DOI
  14. A Nakamura, 2016, Deletion of exons 3–9 encompassing a mutational hot spot in the DMD gene presents an asymptomatic phenotype, indicating a target region for multiexon skipping therapy, Journal of human genetics, 61, 663, 10.1038/jhg.2016.28 · DOI
  15. L Bello, 2016, DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study, Neurology, 87, 401, 10.1212/WNL.0000000000002891 · DOI · Paper page
  16. L Bello, 2016, Genetic diagnosis as a tool for personalized treatment of Duchenne muscular dystrophy, Acta myologica: myopathies and cardiomyopathies: official journal of the Mediterranean Society of Myology, 35, 122
  17. A Aartsma-Rus, 2009, Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations, 30, 293
  18. KR Lim, 2017, Eteplirsen in the treatment of Duchenne muscular dystrophy, Drug design, development and therapy, 11, 533, 10.2147/DDDT.S97635 · DOI · Paper page
  19. A Aartsma-Rus, 2018, Why dystrophin quantification is key in the eteplirsen saga, Nature reviews Neurology, 14, 454, 10.1038/s41582-018-0033-8 · doi:10.1038/s41582-018-0033-8
  20. A Aartsma-Rus, 2020, The 10th Oligonucleotide Therapy Approved: Golodirsen for Duchenne Muscular Dystrophy, Nucleic Acid Ther, 10.1089/nat.2020.0845 · DOI
  21. A Aartsma-Rus, 2019, A Sequel to the Eteplirsen Saga: Eteplirsen Is Approved in the United States but Was Not Approved in Europe, Nucleic Acid Ther, 29, 13, 10.1089/nat.2018.0756 · DOI
  22. S Dhillon, 2020, Viltolarsen: First Approval, Drugs, 80, 1027, 10.1007/s40265-020-01339-3 · DOI · Paper page
  23. JW McGreevy, 2015, Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy, 8, 195
  24. PA t Hoen, 2008, Generation and characterization of transgenic mice with the full-length human DMD gene, J Biol Chem, 283, 5899, 10.1074/jbc.M709410200 · DOI
  25. M Veltrop, 2018, A dystrophic Duchenne mouse model for testing human antisense oligonucleotides, PLoS One, 13, e0193289, 10.1371/journal.pone.0193289 · DOI · Paper page
  26. M Veltrop, 2013, Generation of embryonic stem cells and mice for duchenne research, PLoS Curr, 5
  27. C Beekman, 2018, Use of capillary Western immunoassay (Wes) for quantification of dystrophin levels in skeletal muscle of healthy controls and individuals with Becker and Duchenne muscular dystrophy, PLoS One, 13, e0195850, 10.1371/journal.pone.0195850 · DOI · Paper page
  28. RC Verheul, 2016, Digital Droplet PCR for the Absolute Quantification of Exon Skipping Induced by Antisense Oligonucleotides in (Pre-)Clinical Development for Duchenne Muscular Dystrophy, PLoS One, 11, e0162467, 10.1371/journal.pone.0162467 · DOI
  29. I Gazzoli, 2016, Non-sequential and multi-step splicing of the dystrophin transcript, RNA biology, 13, 290, 10.1080/15476286.2015.1125074 · DOI · Paper page
  30. NA Datson, 2020, Using a State-of-the-Art Toolbox to Evaluate Molecular and Functional Readouts of Antisense Oligonucleotide-Induced Exon Skipping in mdx Mice, Nucleic Acid Ther, 30, 50, 10.1089/nat.2019.0824 · DOI
  31. 2019, Cell-Penetrating Peptide Conjugates of Steric Blocking Oligonucleotides as Therapeutics for Neuromuscular Diseases from a Historical Perspective to Current Prospects of Treatment, 29, 1
  32. CS Young, 2017, Creation of a Novel Humanized Dystrophic Mouse Model of Duchenne Muscular Dystrophy and Application of a CRISPR/Cas9 Gene Editing Therapy, J Neuromuscul Dis, 4, 139, 10.3233/JND-170218 · DOI

Cited by

Metadata

Authors
Yavas, A., Weij, R., van Putten, M., Kourkouta, E., Beekman, C., Puoliväli, J., Bragge, T., Ahtoniemi, T., Knijnenburg, J., Hoogenboom, M. E., Ariyurek, Y., Aartsma-Rus, A., van Deutekom, J., & Datson, N.
Venue
PLOS ONE
Published
2020-12-23
Volume
15
Issue
12
Pages
e0244215
ISSN
1932-6203
Cited by
33
References
2
Language
en
Funders
BioMarin Pharmaceutical

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.